The prevalence of urinary tract infections in type 2 diabetic patients: a systematic review and meta-analysis

Nader Salari¹, Mohammad Mahdi Karami², Shadi Bokaee³, Maryam Chaleshgar², Shamarina Shohaimi⁴, Hakimeh Akbari⁵ and Masoud Mohammadi⁵*¹

Abstract

Background: Urinary tract infection is the most common infection in type 2 diabetic patients. Various studies have reported different outbreaks of urinary tract infections in type 2 diabetic patients. Therefore, the present study aimed to determine the prevalence of urinary tract infections in type 2 diabetic patients during a systematic review and meta-analysis in order to develop interventions to reduce the incidence of urinary tract infections in type 2 diabetic patients.

Methods: In this study, systematic review and meta-analysis of study data related to the prevalence of urinary tract infection in type 2 diabetic patients were conducted using keywords including type 2 diabetes, urinary tract infection, diabetes, prevalence, meta-analysis and their English equivalents in SID, MagIran, IranMedex, IranDoc, Google Scholar, Cochrane, Embase, Science Direct, Scopus, PubMed and Web of Science (WoS) databases from 1993 to 2020. In order to perform the analysis of qualified studies, the model of random-effects was used, and the inconsistency of studies with the $\pm$ index was investigated. Data analysis was performed with Comprehensive Meta-Analysis (Version 2).

Results: Based on a total of 15 studies with a sample size of 827,948 in meta-analysis, the overall prevalence of urinary tract infection in patients with type 2 diabetes was 11.5% (95% confidence interval: 7.8–16.7%). The prevalence of urinary tract infections in diabetic Iranian patients increased with increasing number of years of research, ($p < 0.05$), and with increasing age of participants ($p < 0.05$), but however the prevalence decreased with increasing sample size ($p < 0.05$).

Conclusion: This study shows that urinary tract infections are highly prevalent in patients with type 2 diabetes. Therefore, due to the growing prevalence of diabetes and its complications such as urinary tract infections, the need for appropriate screening programs and health care policies is becoming more apparent.

Keywords: Type 2 diabetes, Urinary tract infection, Diabetes, Prevalence, Meta-analysis
recent years [7, 8]. In 2015, about 415 million adults with type 2 diabetes were reported, which is projected to increase to 642 million by 2040 [7]. The prevalence increased from 4.3% to 9% in men and 5% to 7.9% in women [8]. Type 2 diabetes increases the risk of certain diseases, including cardiovascular disease, eye and blindness problems, amputation of the lower limbs, kidney disease and infectious diseases [9, 10]. The most common infectious disease in diabetic patients is type 2 urinary tract infection (UTI) [11]. It is estimated that 150 million people worldwide suffer from urinary tract infections each year [12].

A urinary tract infection (UTI) is an infection of the urinary system. This type of infection can involve the urethra (a condition called urethritis), kidneys (a condition called pyelonephritis) or bladder (a condition called cystitis) [10–12]. Women are at greater risk of developing a UTI than are men. Infection limited to the bladder can be painful and annoying. However, serious consequences can occur if a UTI spreads to the kidneys [11, 12].

Factors such as immune system disorders, weakening of white blood cells, poor blood supply, bladder dysfunction due to nephropathy and glucosuria can cause urinary tract infections in type 2 diabetic patients [13–22]. Dysuria is a complication of urinary tract infection in diabetic patients due to organ damage and even death due to the complexity of pyelonephritis. Also, these patients experience urinary retention, urgency, and incontinence during the night due to increased urination to excrete excess glucose [23]. The prevalence of urinary tract infections in women is higher than in men, which may be due to the specific structure of the short urinary tract, the shortness of the urethra, and its proximity to the anus in women [24]. Urinary tract infections make it difficult to control blood sugar in diabetic patients, which increases the need for blood sugar monitoring, reduces the quality of life, and imposes significant treatment costs on the patient [25].

Statistics reported from various studies indicate heterogeneity in reported prevalence, indicating the inconsistency and uncertainty of the prevalence of UTI in type 2 diabetes patients. Therefore, since intervention studies on reducing the prevalence of UTI in type 2 diabetes patients require accurate and consistent information to prevent the complications of UTI, the research question is that what is the overall prevalence of UTI in type 2 diabetes patients? The findings from this study could provide a better understanding for the development of more detailed programs to reduce the effects of urinary tract infections and improve people's health.

Methods

The study looked at the systematic review and meta-analysis to find related studies from the SID, MagIran, IranMedex, IranDoc, Cochrane, Embase, Science Direct, Scopus, PubMed and Web of Science (WoS) databases, and the Google Scholar search engine. The articles were obtained using keywords such as prevalence, urinary tract infection, type 2 diabetes and Latin keywords Prevalence, UTI, Type 2 diabetes mellitus and all possible combinations of these words the search strategy for each database was determined.

Keywords were extracted from the Medical Subject Headings (MeSH) database. Keywords related to the studied population (P) were: prevalence, outbreak, Type 2 diabetes mellitus, Type 2 diabetes, diabetes and outcome-related keywords (O) were: UTI, urinary tract infection, infection, morbidity, outcomes.

The search strategy in each database was determined by using the advanced search option and using all possible keyword combinations with the help of AND, and OR operators.

Search strategy in all databases: ((((Type 2 diabetes [Title/Abstract]) OR Type 2 diabetes mellitus [Title/Abstract]) OR diabetes mellitus [Title/Abstract]) AND urinary tract infection [Title/Abstract]) OR UTI [Title/Abstract] OR infection AND prevalence OR Period Prevalence OR Point Prevalence))))), The search strategy for all databases is reported in Table 1.

All related studies were identified in the search process, and the information of these studies was transferred to the information management software (EndNote). Therefore, all possible related articles published from 1993 to 2020 were identified, and their information was transferred to EndNote. In order to maximise the comprehensiveness of the search, the list of sources used in all related articles found in the above search was manually reviewed.

Inclusion criteria

Criteria for entering studies included: studies that examined the prevalence of urinary tract infections in type 2 diabetic patients, descriptive studies, cross-sectional studies, observational studies and studies in which the full text was available.

Exclusion criteria

Criteria for excluding studies include intervention studies, case studies, case–control, cohort, grouping, review and irrelevant studies, studies without sufficient data, repeatability of studies, and uncertainty of study methods. Because the prevalence studied in this study is population-based, only cross-sectional studies were included in the study and other studies such as the case–control
and cohort studies, which may report the prevalence but were group-based, were not included in the study.

**Selection of studies**
Initially, studies that were repeated in various databases searched were removed from this study. The researchers of this study then prepared a list of the titles of all the remaining articles to get obtain articles by evaluating the articles in this list.

In the first stage, screening, the title and abstract of the remaining articles were carefully studied and deleted based on the criteria for including and excluding unrelated articles. In the second stage, i.e. the evaluation of the competence of the studies, the full text of the possible related articles remaining from the screening stage was examined based on the inclusion and exclusion criteria, and in this stage, the unrelated studies were removed.

To prevent bias, all stages of investigation and search were performed based on the PRISMA process by 3 researchers; all sources were reviewed and extracted by two researchers independently. If the articles are not included, the reason for deleting them was mentioned. In cases where there was a disagreement between the two researchers, a third person would review the article. Twenty studies entered the third stage, qualitative assessment.

**Qualitative evaluation of studies**
In order to validate and evaluate the quality of articles (methodological validity and results), a checklist appropriate to the type of study is used. STROBE checklists are commonly used to critique and evaluate qualitative observational studies such as the present study. The STROBE checklist consists of 6 scales or general sections including title, abstract, introduction, methods, results, and discussion. Some of these scales have sub-scales for a total of 32 items. These 32 items represent different methodological aspects of the study, including title, problem statement, study objectives, study type, study statistical population, sampling method, appropriate sample size determination, the definition of variables and procedures, study data collection tools and methods which includes statistical analysis and findings. Accordingly, the maximum score obtained from the qualitative evaluation will be in the STROBE 32 checklist, and considering the score of 16 as the cut-off point, the articles with scores of 16 and above will be considered good and medium quality articles and will be included in the study. Also, 16 articles with poor methodological quality were considered weak and therefore excluded from the study [42] (Table 2).

In the present study, based on the evaluation based on the STROBE checklist, 15 papers entered the systematic review and meta-analysis process as good and moderate methodological quality studies and five papers had poor methodological quality were therefore excluded from the study [26].

**Extracting the data**
Information on all final papers entered into the systematic review and meta-analysis was extracted from a pre-prepared checklist. The checklist included the title of the
## Table 2 Evaluation of the quality of studies with the STROBE checklist

| Row | Author(s) and year of publication | Introduction | Materials and methods | Discussion and conclusion |
|-----|----------------------------------|--------------|-----------------------|---------------------------|
|     |                                   |              |                       |                           |
| 1   | Muller, 2005, [9]                 | +            | +                     | +                         |
| 2   | Fu, 2014, [11]                    | +            | +                     | +                         |
| 3   | Carrondo, 2020, [27]              | +            | +                     | +                         |
| 4   | He, 2018, [28]                    | +            | +                     | +                         |
| 5   | Nicolas, 2017, [29]               | +            | +                     | +                         |
| 6   | Sewify, 2016, [30]                | +            | +                     | +                         |
| 7   | Wilke, 2016, [31]                 | +            | +                     | +                         |
| 8   | Al-rubeaan, 2012, [32]            | +            | +                     | +                         |
| 9   | Yu, 2014, [33]                    | +            | +                     | +                         |
| 10  | Hiriji, 2012, [34]                | +            | +                     | +                         |
| 11  | Hammar, 2010, [35]                | +            | +                     | +                         |
| 12  | Janier, 2009, [36]                | +            | +                     | +                         |
| 13  | Venmans, 2009, [37]               | +            | +                     | +                         |
| 14  | Goswarm, 2001, [38]               | +            | +                     | +                         |
| 15  | Bonadi, 2000, [39]                | +            | +                     | +                         |

**Results**

- Descriptive data
- Participants’ reports
- Report the original data
- The main results of the study
- Other analyzes
- Report key results
- Limitations
- Interpretation of results
- Generalisation
- Budget
- Support
### Table 2 (continued)

| Row | Author(s) and year of publication | Results Descriptive data | Participants' reports | Report the original data | The main results of the study | Other analyzes | Interpretation | Generalisation Budget Support |
|-----|----------------------------------|--------------------------|-----------------------|--------------------------|-------------------------------|----------------|---------------|------------------|
| 2   | Fu, 2014 [11]                    | +                        | +                     | +                        | +                             | +              | +             | +                |
| 3   | Carrondo, 2020 [27]              | +                        | +                     | +                        | +                             | +              | +             | +                |
| 4   | He, 2018 [28]                    | +                        | +                     | +                        | +                             | +              | +             | +                |
| 5   | Nicolas, 2017 [29]               | +                        | +                     | +                        | +                             | +              | +             | +                |
| 6   | Sowry, 2016 [30]                 | +                        | +                     | +                        | +                             | +              | +             | +                |
| 7   | Wilke, 2016 [31]                 | +                        | +                     | +                        | +                             | +              | +             | +                |
| 8   | Al-rubeaan, 2012 [32]            | +                        | +                     | +                        | +                             | +              | +             | +                |
| 9   | Hiriji, 2012 [33]                | +                        | +                     | +                        | +                             | +              | +             | +                |
| 10  | Hammar, 2010 [34]                | +                        | +                     | +                        | +                             | +              | +             | +                |
| 11  | Janifer, 2009 [35]               | +                        | +                     | +                        | +                             | +              | +             | +                |
| 12  | Venmans, 2009 [36]               | +                        | +                     | +                        | +                             | +              | +             | +                |
| 13  | Goswarni, 2001 [37]              | +                        | +                     | +                        | +                             | +              | +             | +                |
| 14  | Bonadi, 2000 [38]                | +                        | +                     | +                        | +                             | +              | +             | +                |
| 15  |                                      |                          |                       |                          |                               |                |               |                  |
article, the author’s first name, year of publication, place of study, sample size, the prevalence of urinary tract infection in type 2 diabetic patients, and mean age.

Statistical analysis
The I² test was used to assess the heterogeneity of the selected studies. In order to investigate the publication error, due to the high volume of samples entered into the study, the Egger test was used at a significance level of 0.05 and the corresponding funnel plot was used. Data analysis was performed using Comprehensive Meta-Analysis software (Version 2).

Results
In this study, systematic review and meta-analysis of data on the prevalence of urinary tract infections in type 2 diabetic patients without time constraints and according to PRISMA guidelines were systematically investigated. Based on an initial search of the database, 1904 possible related articles were identified and transferred to the information management software (EndNote). Out of a total of 1904 identified studies, 173 were duplicates and were eliminated.

Out of 1731 remaining studies in the screening stage, 1650 articles were deleted by reading the title and abstract based on inclusion and exclusion criteria. In the competency assessment phase, 61 of the remaining 81 studies were eliminated by studying the full text of the article based on inclusion and exclusion criteria due to unrelatedness. In the qualitative evaluation stage, through the study of the full text of the article and based on the score obtained from the STROBE checklist, out of the remaining 20 studies, five articles that had poor methodological quality were removed. Finally, 15 studies entered the final analysis (Fig. 1).

Based on the results of the test ($I^2 = 99.9$) and due to the heterogeneity of the selected studies, the random-effects model was used to combine the studies and the common estimate of the prevalence. The total sample size was 872,948 people, and the specifications of the selected articles are given in Table 3.

The probability of publication bias in the results was investigated by funnel plot and Egger test (Fig. 2), which shows that the publication bias was not statistically significant ($p = 0.857$), also the results of Begg and Mazumdar test at the significance level of 0.1 indicate no publication bias was present in the study ($p = 0.552$).

According to the study results, the overall prevalence of urinary tract infection in type 2 diabetic patients was 11.5% (95% CI: 7.8–16.7%) (Fig. 3). Due to the different time range in the studies, the analysis of the subgroup based on the studies time range is mentioned in Table 4. Also, based on the results of subgroup analysis in Table 2, it is reported that the prevalence of urinary tract infections in women with diabetes is higher than men with diabetes ($14.2$ (95% CI 9.7–20.2) vs. $6.1$ (95% CI 3.6–10)). A sensitivity analysis was performed to ensure the stability results, after removing each study results did not change (Fig. 4).

The midpoint of each line indicates the prevalence of urinary tract infections in each study and the rhombic shape of the prevalence of urinary tract infections in type 2 diabetic patients for the entire study.

Using meta-regression, the relationship between year of study and sample size and age of participants in the study with the prevalence of urinary tract infection in type 2 diabetic patients was examined. The prevalence of urinary tract infection was significantly different in all three cases. The prevalence of urinary tract infections in diabetic patients increased with increasing number of years of research, ($p < 0.05$), and with increasing age of participants ($p < 0.05$), but however the prevalence decreased with increasing sample size ($p < 0.05$) (Figs. 5, 6, 7).

Discussion
According to the studies studied, the prevalence of urinary tract infections in patients with type 2 diabetes varies in different countries of the world. On average, 10.16% of patients with type 2 diabetes who participated in the study had a urinary tract infection, compared with 33.29% at Nicholas 2017 (conducted in the United States and Germany) and at Hirji 2012 (in the United States, Germany, and Sweden), with a prevalence rate of 2.55%, has the highest and lowest prevalence rates, respectively [29, 34]. People with type 2 diabetes have a higher chance of developing infections than non-diabetics [40, 41]. Providing accurate statistics can help health policy-makers make effective decisions and reduce costs and costs of health care. The prevalence reported in this study is an accurate value for policy and intervention measures.

A person with UTI is considered to have certain microbial pathogens in his or her urinary tract [42]. In people with type 2 diabetes, the main organism that causes urinary tract infections is the *E. coli* bacterium [3, 39, 43]. Bacterial urinary tract infections are clinically distinct. Septic bacteria cause urinary tract infections with apparent symptoms such as increased frequency of urination, dysuria, haematuria, and a painful touch of the hyperaemic area, while aseptic bacteria cause urinary tract infection without obvious symptoms [42]. It is said that the prevalence of aseptic bacteria in people with diabetes is three times higher than in normal people [44]. Also, asymptomatic bacterial infections are more common in these people, which does not indicate that their upper
In people with type 2 diabetes, several different mechanisms may increase the risk of urinary tract infections, including diabetic nephropathy, autonomic neuropathy, immune system disorders, and glucosuria [9, 46].

Diabetic nephropathy leads to disorders such as protein excretion and severe glucosuria. Neurological damage associated with high blood sugar levels can adversely affect the ability of the bladder sensation. Sensory bladder sensory disturbances cause urinary retention, and increases urinary tract infections [47–51].

Diabetes reduces blood circulation, so as diabetes lengthens, it weakens the immune system, which is reduced by treating certain cytokines such as IL-6 and other anti-inflammatory cytokines in a diabetic patient. On the other hand, there are abnormal leukocytes. In diabetics and impaired phagocytic function, leukocytes due to high glucose levels in diabetic patients may weaken the immune system of these patients [52–56].

Apart from BMI, UTI is significantly associated with age, sex, recent UTI history and microalbuminuria [57].

It should be noted that there is a difference of opinion regarding the effect of diabetes duration and blood
sugar control on UTI. The study of Vismanthan linked the duration of diabetes to UTI, but this was in contrast to findings by He 2018 [26, 36]. The relationship between blood sugar control and UTI is also highly controversial. It is effective in UTI, but in Greeling’s study, blood sugar control did not affect whether or not UTI was present [57–59].

With increasing age, the risk of developing UTI in both sexes, especially in women, increases. For example, in the Carrondo study, the UTI rate in people aged 18–64 was 9%, compared with 27.5% in people over 85 years old [27]. In all of the articles reviewed, the UTI rate in women was higher than in men, which appears to be related to bladder neurological dysfunction, physiological

Table 3 Characteristics of included studies on prevalence of urinary tract infection

| Author, year, [References] | Mean age (year) | Country       | Sample size | Study time range                              | Prevalence % |
|-----------------------------|-----------------|---------------|-------------|-----------------------------------------------|--------------|
| Muller, 2005, [9]           | 65.7            | Netherlands   | 6712        | 1 year                                       | 6.9          |
| Fu, 2014, [11]              | 56              | USA           | 89,790      | 1 year (1 Jan 2010–1 Dec 2010)                | 9.4          |
| Carrondo, 2020, [27]        | 71              | Portugal      | 7347        | 1 year (1 Jan–1 Dec 2015)                     | 16.2         |
| He, 2018, [28]              | 59.3            | China         | 3264        | 3 years and 4 months (Mar 2013–Jul 2016)      | 12.5         |
| Nicolas, 2017, [29]         | 60.2            | USA, Germany  | 392,995     | 9 years (2006–2014)                           | 33.3         |
| Sewify, 2016, [30]          | 55.5            | Kuwait        | 722         | 3 years (Apr 2011–Mar 2014)                   | 34.9         |
| Wilke, 2016, [31]           | 73.8            | USA, Germany  | 456,586     | 2 years (2010–2012)                           | 9.2          |
| Al-rubeaan, 2012, [32]      | 51.9            | Saudi Arabia  | 1000        | 18 years (1993–2009)                          | 25.3         |
| Yu, 2014, [33]              | 62.5            | USA           | 73,151      | 3 years and 8 months (1 Jan 2008–9 Sep 2011)  | 8.2          |
| Hiriji, 2012, [34]          | 63              | USA, Germany, Sweden | 135,920 | 1 year                                    | 2.5          |
| Hammar, 2010, [35]          | 57.4            | Sweden        | 6016        | 3 years (2004–2007)                           | 2.3          |
| Janifer, 2009, [36]         | –               | India         | 1157        | 1 year                                       | 42.8         |
| Venmans, 2009, [37]         | 67              | Netherlands   | 6343        | 1 year (2000–2002)                            | 2.7          |
| Goswarni, 2001, [38]        | 33              | India         | 155         | 6 months                                     | 9.03         |
| Bonadi, 2000, [39]          | 69.4            | Italy         | 490         | 2 years (1996–1998)                           | 18.1         |

Fig. 2 Funnel plot results from the overall prevalence of urinary tract infection in type 2 diabetic patients
bladder changes due to aging or shortness of breath, and proximity to the anus among women [24, 27].

For example, a study by Carrondo 2020 in Portugal found that 23.6% of women with type 2 diabetes had UTI, compared to only 10.5% of men with type 2 diabetes [27]. A 2011 study in Fu 2014 [11] reported a 14% increase in UTI incidence in women with type 2 diabetes and 9.1% in non-diabetic women, compared with 5% in men with type 2 diabetes and 2.4% in non-diabetic men.

The association between diabetes, urinary tract infection and gender has been well established [11]. In a 2018 study in China, out of 1072 women with type 2 diabetes in the study, 341 people were infected, and of the 1783 men with type 2 diabetes in the study, only 68 people had a urinary tract infection [28]. In connection with the study of Venmans, where the prevalence rate of UTI in men is higher than in women, it is necessary to provide the necessary explanations. In this study, the prevalence rate of recurrent bacterial cystitis in women was 2%, while in men, the prevalence of bacterial cystitis and prostatitis was 3%, so this could be a possible cause of the discrepancy [37].

Therefore, being female can be considered a risk factor for urinary tract infection. The prevalence of UTI in Stage 1 diabetics is higher than in Stage 2, because Stage 2 diabetics already have blood sugar control [8, 60].

For example, in the Carrondo 2020 study, the prevalence rate of UTI in diabetic patients was Stage 1, 24.4%, and in diabetic patients, Stage 2, was 4.8% [27]. In an epidemiological study, the prevalence of urinary tract infections was highest in developing countries (24%) and 12.9% and 19.6% in the United States and Europe, respectively [61]. One of the limitations of this study, which is mainly due to the review of the study, is the following:

| Study name | Event rate | Lower limit | Upper limit | Z-Value | p-Value | Relative weight |
|------------|------------|-------------|-------------|---------|---------|----------------|
| Carrondo   | 0.162      | 0.154       | 0.171       | 51.905  | 0.000   | 6.73           |
| He         | 0.125      | 0.114       | 0.137       | 30.753  | 0.000   | 6.72           |
| sejify     | 0.349      | 0.316       | 0.385       | 7.983   | 0.000   | 6.68           |
| Nicolas    | 0.333      | 0.328       | 0.338       | 64.896  | 0.000   | 6.74           |
| Yu         | 0.082      | 0.080       | 0.084       | 179.245 | 0.000   | 6.74           |
| Fu         | 0.094      | 0.092       | 0.096       | 198.117 | 0.000   | 6.74           |
| Hirj      | 0.026      | 0.025       | 0.026       | 211.735 | 0.000   | 6.74           |
| Hammar     | 0.024      | 0.020       | 0.028       | 43.832  | 0.000   | 6.67           |
| Janifer    | 0.428      | 0.400       | 0.457       | 4.892   | 0.000   | 6.71           |
| Muller     | 0.069      | 0.063       | 0.075       | 54.032  | 0.000   | 6.72           |
| wilke      | 0.093      | 0.092       | 0.094       | 446.999 | 0.000   | 6.74           |
| goswarni   | 0.090      | 0.094       | 0.147       | 8.243   | 0.000   | 6.07           |
| bonadio    | 0.182      | 0.150       | 0.218       | 12.847  | 0.000   | 6.61           |
| venmans    | 0.027      | 0.024       | 0.032       | 45.418  | 0.000   | 6.69           |
| Al-rubeaan  | 0.253     | 0.227       | 0.281       | 14.884  | 0.000   | 6.69           |

Table 4 | Analysis of the subgroup based on the studies time range

| Study time range | N | Sample size | $i^2$ | Prevalence (95% CI) |
|------------------|---|-------------|------|---------------------|
| 1 Year           | 7 | 247,424     | 99.9 | 8.9 (95% CI 4.5–16.8) |
| 1–4 Years        | 6 | 540,229     | 99.9 | 11 (95% CI 8.9–13.5)  |
| > 4 Years        | 2 | 40,290      | 96.4 | 29.3 (95% CI 221–37.7) |
| Sex              |   |             |      |                     |
| Man              | 14| 392,835     | 99.9 | 6.1 (95% CI 3.6–10)  |
| Women            | 14| 434,388     | 99.9 | 14.2 (95% CI 9.7–20.2) |

Fig. 3 | Overall prevalence of urinary tract infection in type 2 diabetic patients and 95% confidence interval
**Meta Analysis**

| Study name | Statistics with study removed | Event rate (95% CI) with study removed |
|------------|--------------------------------|---------------------------------------|
| Carrondo   | 0.112, 0.075, 0.166, 8.981, 0.000 |                                      |
| He         | 0.115, 0.076, 0.168, 8.948, 0.000 |                                      |
| sewify     | 0.115, 0.070, 0.155, 9.449, 0.000 |                                      |
| Nicolas    | 0.116, 0.081, 0.136, 14.470, 0.000 |                                      |
| Yu         | 0.118, 0.076, 0.179, 8.113, 0.000 |                                      |
| Fu         | 0.117, 0.074, 0.180, 7.798, 0.000 |                                      |
| Hirji      | 0.118, 0.089, 0.180, 9.353, 0.000 |                                      |
| Hammar     | 0.118, 0.086, 0.186, 8.470, 0.000 |                                      |
| Janifer    | 0.103, 0.069, 0.151, 9.633, 0.000 |                                      |
| Muller     | 0.110, 0.080, 0.175, 8.741, 0.000 |                                      |
| wilke      | 0.117, 0.068, 0.193, 6.675, 0.000 |                                      |
| goswarni   | 0.117, 0.078, 0.171, 8.920, 0.000 |                                      |
| bonadio    | 0.112, 0.074, 0.164, 9.133, 0.000 |                                      |
| venmans    | 0.117, 0.085, 0.185, 8.513, 0.000 |                                      |
| Al-ruebaan  | 0.118, 0.072, 0.160, 9.274, 0.000 |                                      |
|            | 0.115, 0.078, 0.167, 9.286, 0.000 |                                      |

**Fig. 4** Results of sensitivity analysis

![Regression of Sample on Logit event rate](image)

**Fig. 5** Meta-regression of the relationship between sample size and prevalence of urinary tract infection in type 2 diabetic patients
1. Not all articles are available.
2. The method of measuring the variables studied is not the same in all studies.
3. Ignoring nutrition and lifestyle in all studies.
4. Due to the inconsistency of the study conditions and the volume of the samples, it is not possible to generalise the results of the present study.
5. It is hoped that the present study provides an organised and complete perspective for developing screening programs, appropriate planning, and health care policies to prevent the increase in the incidence and complications of UTI in people with type 2 diabetes.

**Conclusion**

This study shows that urinary tract infections are highly prevalent in patients with type 2 diabetes. Therefore, due to the growing prevalence of diabetes and its
complications, such as urinary tract infections, the need for appropriate screening programs and health care policies is becoming more apparent.

Abbreviations
ULTI: Urinary tract infection; SID: Scientific Information Database; WoS: Web of Science; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analysis; STROBE: Strengthening the Reporting of Observational Studies in Epidemiology for cross-sectional Study.

Acknowledgements
We hereby express our gratitude and appreciation to the Student Research Committee of Kermanshah University of Medical Sciences.

Authors’ contributions
MM and NS and MMK and MCH contributed to the design. MM statistical analysis, participated in most of the study steps. SHR and SHS and HA prepared the manuscript. NS and MM assisted in designing the study, and helped in the interpretation of the study. All authors have read and approved the content of the manuscript.

Funding
By Student Research Committee of Kermanshah University of Medical Sciences, Deputy for Research and Technology, Kermanshah University of Medical Sciences (IR) (3009610). This deputy has no role in the study process.

Availability of data and materials
Datasets are available through the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
Ethics approval was received from the ethics committee of the Deputy of Research and Technology, Kermanshah University of Medical Sciences (3009610).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran. 2 Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran. 3 Faculty of Health and Life Sciences, School of Life Sciences, Coventry University, Coventry, UK. 4 Department of Biology, Faculty of Science, University Putra Malaysia, Serdang, Selangor, Malaysia. 5 Cellular and Molecular Research Center, Gerasht University of Medical Sciences, Gerasht, Iran.

Received: 7 October 2021   Accepted: 19 January 2022
Published online: 05 February 2022

References
1. Hu FB. Globalisation of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34(6):1249–57.
2. De Fronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303.
3. Patterson JE; Androhle VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. 1997;11(3):735–50.
4. Josh N, Caputo GM, Weitkamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med. 1999;341(25):1906–12.
5. Boyko EJ, Fihn SD, Scholes D, Abraham L, Monsey B. Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women. Ann J Epidemiol. 2005;161(6):557–64.
6. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26(2):510–3.
7. Zheng Y, Levy SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:488–98.
8. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–1530.
9. Muller UMAJ, Gotter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281–8.
10. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510–3.
11. Fu AZ, Iglay K, Qiu Y, Engel S, Shankar R, Brodovicz K. Risk characterisation for urinary tract infections in subjects with newly diagnosed type 2 diabetes. J Diabetes Complicat. 2014;28(6):805–10.
12. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis. 2001;33(1):89–94.
13. Ellenberg M. Diabetic neuropathy: clinical aspects. Metabolism. 1976;25:1627–55.
14. Ellenberg M, Weber H. The incipient asymptomatic diabetic bladder. Diabetes. 1996;15:524–5.
15. Frimodt-Moller C. Diabetic cystopathy I–IV. Dan Med Bull. 1976;23:267–94.
16. Rodrigue-P-Velasquez A, Yoder IC, Velasquez PA, et al. Imaging the effects of diabetes in the genitourinary system. Radiographics. 1995;15:1051.
17. Wheat LJ. Infection and diabetes mellitus. Diabetes Care. 1980;3:187–97.
18. Sridhar CB, Anjana S, Mathew JT. Acute Infections. In: Ahuja MMS, Tripathy BB, Sam Moses GP, Chandalia HB, Das AK, Rao PV, editors. RSSDI Text Book of Diabetes Mellitus. Hyderabad, India. 2002. chap. 34. p. 471–478.
19. Geerlings SE, Stolk RP, Camps MJ, et al. Asymptomatic bacteriuria can be considered a diabetic complication in women with diabetes mellitus. Adv Exp Med Biol. 2000;485:559–14.
20. Fünfstück R, Nicolle LE, Hanefeld M, Naber KG. Urinary tract infection in patients with diabetes mellitus. Clin Nephrol. 2012;77(1):40–8.
21. Truzzi JC, Almeida FM, Nunes EC, Sadi MV. Residual urinary volume and urinary tract infection—when are they linked? J Urol. 2008;180(1):182–5.
22. Hosking DJ, Bennett T, Hampton JR. Diabetic autonomic neuropathy. Diabetes. 1978;27(10):1043–55.
23. Bonadio M, Costarella S, Morelli G, Tartaglia T. The influence of diabetes mellitus on the spectrum of uropathogens and the antimicrobial resistance in elderly adult patients with urinary tract infection. BMC Infect Dis. 2006;6:54.
24. Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015;8:129–36.
25. Gotter KJ, Hak E, Zuithoff NP, Hoepelman AI, Rutter GE. Risk of recurrent acute lower urinary tract infections and prescription pattern of antibiotics in women with and without diabetes in primary care. Fam Pract. 2010;27(4):379–85.
26. Shafiei M, Nozari B, Tabibi H, Mahdavi M, Hedayati M, Hoshiar M. Prevalence of different types of energy-protein malnutrition in hemodialysis patients in Tehran in 2008. Iranian Journal of Nutrition Sciences and Food Technology, Fifth Year, 2009; Number 1, pp. 17–24 [Persian].
27. Carrondo MC, Moita JJ. Potentially preventable urinary tract infection in patients with type 2 diabetes—a hospital-based study. Obes Med. 2020;17:100190.
28. He K, Hu Y, Shi JC, Zhu YQ, Mao XM. Prevalence, risk factors and microorganisms of urinary tract infections in patients with type 2 diabetes mellitus: a retrospective study in China. Ther Clin Risk Manag. 2018;14:403–8.
29. Nichols GA, Brodovicz KG, Kimes TM, Dûrez-Luyet A, Bartels DB. Prevalence and incidence of urinary tract and genital infections among patients with and without type 2 diabetes. J Diabetes Complicat. 2017;31(11):1587–91.
30. Sewify M, et al. Prevalence of urinary tract infection and antimicrobial susceptibility among diabetic patients with controlled and uncontrolled glycaemia in Kuwait. J Diabetes Res. 2016;2016:6573215.
31. Wilke T, et al. Healthcare burden and costs associated with urinary tract infections in type 2 diabetes mellitus patients: an analysis based on a large sample of 436,386 German patients. Nephron. 2016;122(3):215–26.
32. Al-Rubeaan KA, Moharram O, Al-Naeqeb D, Hassan A, Raffullah MR. Prevalence of urinary tract infection and risk factors among Saudi patients with diabetes. World J Urol. 2013;31(3):573–8.
33. Yu S, Fu AZ, Qiu Y, Engel SS, Shankar R, Brodovicz KG, Rajpathak S, Radican L. Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S. J Diabetes Complicat. 2014;28(5):621–6.
34. Hjiri J, Guo Z, Andersson SW, Hammar N, Gomez-Macario A. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complicat. 2012;26(6):513–6.
35. Hammar N, Farahmand B, Gran M, Joelsson S, Andersson SW. Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials. Pharmacoepidemiol Drug Saf. 2010;19(12):1287–92.
36. Janifer J, Gheratalikhahni S, Satyavani K, Viswanathan V. Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects. Indian J Nephrol. 2010;20(2):120.
37. Venmans LM, et al. A clinical prediction rule for urinary tract infections in patients with type 2 diabetes mellitus in primary care. Epidemiol Infect. 2009;137(2):166–72.
38. Goswami R, et al. Prevalence of urinary tract infection and renal scars in patients with diabetes mellitus. Diabetes Res Clin Pract. 2001;53(3):181–6.
39. Bonadio M, et al. Urinary tract infection in diabetic patients. Urol Int. 1999;63(4):215–9.
40. de Lastours V, Foxman B. Urinary tract infection in diabetes: epidemiologic considerations. Curr Infect Dis Rep. 2014;16(1):389.
41. Schmiemann G, Kniehl E, Gebhardt K, et al. The diagnosis of urinary tract infection: a systematic review. Dtsch Arztebl Int. 2010;107:361–7.
42. Lye WC, Chop RK, Lee EJ, Kumasasinghe G. Urinary tract infections in patients with diabetes mellitus. J Infect. 1992;24:169–74.
43. Shah BV, Chawla RP, Acharya VN. Study of urinary tract infection in diabetic subjects. J Assoc Physian India. 1984;82:1037–40.
44. Boroumand MA, Sam L, Abbasi SP, Salarifar M, Kasaiaan E, Forghani S. Asymptomatic bacteriuria in type 2 Iranian diabetic women: a cross sectional study. BMC Womens Health. 2006;6:4.
45. Robbins SL, Tucker AW. The cause of death in diabetes. N Engl J Med. 1944;231:865–8.
46. Delamare M, Maugendre D, Moreno M, Le Goff M-C, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med. 1992;14:29–34.
47. Geerlings SE, Stolk RP, Camps MJL, Netten PM, Collot TJ, Hoepelman AIM. Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care. 2000;23(12):1737–41.
48. Szucs S, Cserhati I, Csarpo G, Balazs V. The relation between diabetes mellitus and infections of the urinary tract. A clinical, qualitative and quantitative bacteriological study based upon 300 diabetics and 200 controls. Am J Med Sci. 1960;240:186–91.
49. Johnsson KM, Ptaszyńska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27(5):473–8.
50. Hosking DJ, Bennett T, Hampton JR. Diabetic autonomic neuropathy. Diabetes. 1978;27:1043–54.
51. Truusi JF, Almeida FM, Nunes EC, Sadi MV. Residual urinary volume and urinary tract infection—when are they linked? J Urol. 2008;180:182–5.
52. Geerlings SE, Brouwer EC, van Kessel KPM, Gaaster W, Hoepelman AM. Cytokine secretion is impaired in women with diabetes mellitus. In: Genes and Proteins Underlying Microbial Urinary Tract Vinulence, vol. 485 of Advances in Experimental Medicine and Biology, pp. 255–262. Springer, 2000.
53. Bagdade JD, Root RK, Bulger RJ. Impaired leucocyte function in patients with poorly controlled diabetes. Diabetes. 1974;23:9–15.
54. Bybey JD, Rogers DE. The phagocytic activity of polymorphonuclear leukocytes obtained from patients with diabetes mellitus. J Lab Clin Med. 1964;64:1.
55. Drachman RH, Root RK, Wood WB Jr. Studies on the effect of experimentanl nonketotic diabetes mellitus on antibacterial defenses: I. Demonstra- tion of a defect in phagocytosis. J Exp Med. 1966;124:227.
56. Mowat AG, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971;284:621–7.
57. Guy Nield H. Urinary tract infection. Medicine. The Medicine publishing company Ltd; 2003. pp. 85–90.
58. Geerlings SE, Stolk RP, Camps MJL, et al. Asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes Mellitus Women Asymptomatic Bacteriuria Utrecht Study Group. Diabetes Care. 2000;23:744–9.
59. Schmitt JK, Fawcett CJ, Gullickson G. Asymptomatic bacteriuria and hemoglobin A1. Diabetes Care. 1986;9:518–20.
60. Ljungqvist O, Nygren J, Sood M, et al. Metabolic perioperative management: novel concepts. Curr Opin Crit Care. 2005;11:295–9.
61. Tandogdu Z, Wagenlehner FM. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29:73–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.